LIV Emles at Home ETF

Fourth graph, URL should read: http://www.samaritanpharma.com/images/havestemcellsarrived.pdf (sted http://www.chiefexecutive.net/ME2/dirmod.asp?sid=&nm=&type=Publish ing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791 &tier=4&id=A83BC9A72A074876BCA05E0ED18D56E2). The corrected release reads: SAMARITAN'S ADULT STEM CELL DRUG DISPLAYS MONEY-MAKING SIGNS Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today its Alzheimer's adult stem cell drug SP-sc04, which induces dormant brain neuronal stem cells to differentiate rapidly into adult neuron cells, is progressing through preclinical studies with promising results. According to a CEO Magazine March 2006 article titled "Have Stem Cells Arrived?" Fran Hawthorne stated, "signs point to an emerging, money-making industry" and William R. Brody, president of Johns Hopkins University, is quoted, "I don't think I have ever seen anything that has the broad potential that stem cell technology has." "We are extremely pleased with the progress and the potential of SP-04. Although it is early stage, each preclinical study we accomplish gives us hope that we might have an extraordinary treatment for the mind robbing disease of Alzheimer's," stated Dr. Greeson, CEO of Samaritan. http://www.samaritanpharma.com/images/havestemcellsarrived.pdf. Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a small-cap biotech, driven to discover, develop and commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer and heart disease. Look at www.samaritanpharma.com. Please register on Web site so we can notify you of upcoming conference calls, news and events. Disclaimer The company disclaims any information that is created by an outside party, and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.